论文部分内容阅读
长期以来绝大多数化疗药物的疗效在不同个体间的差异受到临床医生的高度关注,其药物反应和毒性不仅与患者的年龄、性别以及药物间相互作用等因素有关,而且和参与药物代谢的蛋白或酶的表达水平有关。单核苷酸多态性是基因组中最常见的一种遗传变异,为了揭示个体之间因基因学的差异导致的化疗药物反应以及毒副作用的差异性,近年来对单核苷酸多态性与化疗药物反应及毒性之间相关性的研究和报道逐渐增多。但对各种单核苷酸多态性能否作为化疗药物反应及毒副作用的预测指标未得出统一定论。本文以消化道恶性肿瘤常用化疗药物为例,分别对5-氟尿嘧啶(5-FU)类、铂类、紫杉类和伊立替康相关的单核苷酸多态性(SNP)进行综述。
For a long time the vast majority of chemotherapeutic drugs have different therapeutic effects among different individuals and are highly concerned by clinicians. The drug response and toxicity are not only related to the patient’s age, sex and drug-drug interactions, but also to the proteins involved in drug metabolism Or the level of enzyme expression. Single nucleotide polymorphisms (SNPs) are the most common genetic variation in the genome. In order to reveal the differences in the chemotherapeutic drugs and the toxicities and side effects caused by differences in the genotypes between individuals, single nucleotide polymorphisms Research and reports on the correlation between chemotherapy response and toxicity have been increasing. However, whether single nucleotide polymorphisms can be used as predictors of chemotherapeutic drug response and side effects has not been elucidated. In this paper, chemotherapy drugs commonly used in gastrointestinal malignancies as an example, 5-fluorouracil (5-FU), platinum, taxol and irinotecan-related single nucleotide polymorphisms (SNPs) were reviewed.